Cyanoacrylate spray for treatment of difficult-to-control GI bleeding.
BACKGROUND
Although endoscopic therapy is highly effective for control of GI bleeding, a small proportion of patients experience persistent bleeding and may require radiologic or surgical intervention. Experience with cyanoacrylate spray for treatment of difficult-to-control GI bleeding is limited.


OBJECTIVE
To evaluate the efficacy and safety of an endoscopic cyanoacrylate spray technique for treatment of difficult-to-control GI bleeding.


METHODS
Case series.


METHODS
Two tertiary-care centers.


METHODS
This study involved consecutive patients with overt GI bleeding who were treated with n-butyl-2-cyanoacrylate spray during endoscopy for persistent bleeding despite conventional hemostatic therapies.


METHODS
Cyanoacrylate spray.


METHODS
Hemostasis, rebleeding, adverse events, and technical failure associated with cyanoacrylate spray.


RESULTS
Five patients were treated with cyanoacrylate spray during endoscopy for persistent bleeding (duodenal ulcer in 3, gastric vascular ectasia in 1, rectal postpolypectomy bleeding in 1) after failed conventional therapies. Immediate hemostasis and technical success were achieved in all patients. At a median follow-up of 42 days (range 38-120 days), 2 patients developed recurrent bleeding. One patient experienced rebleeding 2 days after the procedure, subsequently requiring radiographic intervention and surgery. Another patient had recurrent bleeding from a different bleeding source 18 days after the procedure. No adverse events attributed to the cyanoacrylate spray were observed.


CONCLUSIONS
Small number of patients.


CONCLUSIONS
In patients with difficult-to-control GI bleeding failing conventional endoscopic therapies, cyanoacrylate spray was effective in achieving immediate hemostasis. Prospective studies with a larger number of patients to evaluate the role of the cyanoacrylate spray technique during endoscopy for GI bleeding are needed.
Division of Gastroenterology, Department of Medicine, Loma Linda University Medical Center, Loma Linda, California 92354, USA.
Sukhpreet S
SS
Walia
Aadesh
A
Sachdeva
John J
JJ
Kim
Donald J
DJ
Portocarrero
Terence D
TD
Lewis
Yan S
YS
Zhao
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004381:Duodenal Ulcer / Q000150:complications*; D004659:Enbucrilate / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D020252:Gastric Antral Vascular Ectasia / Q000150:complications; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy*; D016558:Hemostasis, Endoscopic / Q000379:methods*; D006801:Humans; D007417:Intestinal Polyps / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010438:Peptic Ulcer Hemorrhage / Q000150:complications / Q000628:therapy; D019106:Postoperative Hemorrhage / Q000209:etiology / Q000628:therapy*; D012002:Rectal Diseases / Q000601:surgery; D012008:Recurrence; D019233:Retreatment / Q000379:methods
D004659:Enbucrilate